- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Compound class||Synthetic organic|
|Approved drug?||Yes (FDA (2018), EMA (2019))|
|International Nonproprietary Names|
|PF-00299804 | PF00299804 | Vizimpro®|
|Dacomitinib is a second-generation, irreversible pan inhibitor of HER tyrosine kinases (EGFR, and ERBBs) that was developed by Pfizer.
Results from the ARCHER 1050 Phase 3 randomised, open-label trial (NCT01774721) that directly compared dacomitinib against gefitinib, as first-line treatment for patients with EGFR-mutation +ve non-small-cell lung cancer (NSCLC), reported that dacomitinib significantly increased progression-free survival and overall survival compared to gefitinib . Dacomitinib's use may be limited in NSCLC patients with brain metastases, as these patients were excluded from the trial because dacomitinib's ability to cross the blood-brain-barrier has not been fully confirmed. This is unlike osimertinib (another third-generation irreversible EGFR inhibitor) which has confirmed brain penetrance, and which does not appear to cause the same dose-limiting toxicities that afflict dacomitinib. In April 2018 both the FDA and EMA accepted regulatory submissions (New Drug Application and Marketing Authorization Application respectively) for review of dacomitinib as a therapy for metastatic NSCLC with EGFR-activating mutations. The FDA granted Priority Review status for the submitted NDA.
|CAS Registry No.||1110813-31-4|
|GtoPdb PubChem SID||178103994|
|RCSB PDB Ligand||1C9|
|Search Google for chemical match using the InChIKey||LVXJQMNHJWSHET-AATRIKPKSA-N|
|Search Google for chemicals with the same backbone||LVXJQMNHJWSHET|
|Search PubMed clinical trials||dacomitinib|
|Search PubMed titles||dacomitinib|
|Search PubMed titles/abstracts||dacomitinib|
|Search UniChem for chemical match using the InChIKey||LVXJQMNHJWSHET-AATRIKPKSA-N|
|Search UniChem for chemicals with the same backbone||LVXJQMNHJWSHET|
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.✖
Cat. No. 6231